Citalopram Tablet
Product Images NDC 71610-412

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Citalopram (NDC 71610-412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 40 mg (71610 0412 60)

Label for Citalopram USP 40 mg oral tablets, packaged in a container of 90 tablets. The label includes storage instructions to keep between 20-25 degrees Celsius, away from light and moisture, and out of reach of children. The product is manufactured by Imvagen Pharmaceuticals Inc. and labeled by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, Tennessee.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 01)

Chemical structure of citalopram hydrobromide, showing the molecular arrangement including fluorophenyl and dimethylaminopropyl groups with a bromide ion (HBr).*

FDA Label Image

Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 02)

A data table titled "Table 1" presenting the drug-placebo difference in the number of cases of suicidality per 1000 patients treated, categorized by age range. The table shows increases compared to placebo for age groups under 18 and 18-24, and decreases compared to placebo for age groups 25-64 and 65 and over.*

FDA Label Image

Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 03)

Table showing treatment-emergent adverse events incidence in placebo-controlled clinical trials of Citalopram versus placebo. It details percentage of patients reporting events across various body systems such as autonomic nervous system, central and peripheral nervous system, gastrointestinal, general, musculoskeletal, psychiatric, respiratory, and urogenital disorders, comparing 1063 Citalopram patients to 446 placebo patients.*

FDA Label Image

Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 04)

Table presenting adverse events associated with discontinuation of treatment in short-term, placebo-controlled depression trials comparing Citalopram and placebo. It lists percentages of patients discontinuing due to adverse events across various body systems, such as general, gastrointestinal, nervous system, and psychiatric disorders, with specific events like nausea, dizziness, and insomnia.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.